Ionis Pharma (IONS) Licenses IONIS-HTT Rx to Partner Roche Following Successful Phase 1/2a Study in Patients with Huntington's Disease
Tweet Send to a Friend
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Roche has exercised its option to license IONIS-HTTRx following the completion ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
